Substance Use Disorder Clinical Trials

Trials for someone you care about with substance use disorder.

Mental Health

Recruiting Drug Device Behavioral Older adults Healthy volunteers

14 trials

Testing Pegozafermin against a placebo for metabolic dysfunction-associated steatohepatitis (MASH) /

Explore this study →

There are 2 groups in this study. Group A receives Pegozafermin. Group B, the placebo group, receives Placebo.

Sites in Vancouver, Calgary and 5 more cities

Phase 3
2 groups
Sites in Calgary, Vancouver and 5 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis · Hoffmann-La Roche

Testing Efruxifermin against a placebo for NASH - nonalcoholic steatohepatitis

Explore this study →

There are 2 groups in this study. Group A receives Efruxifermin. Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 3 more cities

Phase 3
2 groups
Sites in Edmonton, Toronto and 3 more cities
Recruiting

Official title: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NASH - Nonalcoholic Steatohepatitis · Akero Therapeutics, Inc

Testing Naloxone Hydrochloride with Buprenorphine hydrochloride and for opioid use disorder

Explore this study →

Everyone in this study is in one group, which receives one or more of: Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg) and Buprenorphine extended-release injection (300 mg/1.5 mL).

2 sites in Vancouver

Phase 4
1 group
2 sites in Vancouver
Recruiting

Official title: Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial

Opioid Use Disorder · Pouya Azar

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for substance use disorder.

Testing Bupivacaine-epinephrine for opioid use

Explore this study →

There are 2 groups in this study. Group A receives Bupivacaine-epinephrine. Group B, the comparison group, receives Bupivacaine-epinephrine.

One site, in Hamilton

Phase 2
2 groups
One site, in Hamilton
Recruiting

Official title: Timing of TAP Blocks in Bariatric Surgery

Opioid Use · McMaster University

Testing Efimosfermin alfa against a placebo for non-alcoholic fatty liver disease

Explore this study →

There are 3 groups in this study. Groups A and B receive Efimosfermin alfa. Group C, the placebo group, receives Placebo.

One site, in Québec

Phase 3
3 groups
One site, in Québec
Recruiting

Official title: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-alcoholic Fatty Liver Disease · GlaxoSmithKline

Testing Standardized Prescription for opioid use

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Standardized Prescription. Group B receives no study treatment and is followed for comparison.

One site, in Toronto

2 groups
One site, in Toronto
Recruiting

Official title: Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery

Opioid Use · University Health Network, Toronto

Testing Aurora 1:1 Drops (Indica) against a placebo for opioid use disorder

Explore this study →

There are 2 groups in this study. Group A receives Aurora 1:1 Drops (Indica). Group B, the placebo group, receives Placebo.

One site, in Vancouver

Phase 2
2 groups
One site, in Vancouver
Recruiting

Official title: Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

Opioid Use Disorder · BC Centre on Substance Use

Testing Psilocybin for alcohol use disorder

Explore this study →

There are 2 groups in this study. Group A receives Psilocybin. Group B, the comparison group, receives Psilocybin.

One site, in Calgary

Phase 2
2 groups
One site, in Calgary
Recruiting

Official title: Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Alcohol Use Disorder · University of Calgary

Testing Brenipatide against a placebo for opioid use disorder

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Brenipatide and Buprenorphine. Group D, the placebo group, receives Placebo and Buprenorphine.

Sites in Toronto, Calgary and 5 more cities

Phase 2
4 groups
Sites in Calgary, Courtice and 5 more cities
Recruiting

Official title: A Study of Brenipatide in Participants With Opioid Use Disorder

Opioid Use Disorder · Eli Lilly and Company

Testing Psilocybin-assisted Psychotherapy for opioid dependence

Explore this study →

Everyone in this study is in one group and receives Psilocybin-assisted Psychotherapy.

One site, in Kelowna

Phase 2
1 group
One site, in Kelowna
Recruiting

Official title: Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

Opioid Dependence · University of British Columbia

Testing GSK4532990 against a placebo for alcoholic liver diseases

Explore this study →

There are 5 groups in this study. Groups A, B, C and D receive GSK4532990. Group E, the placebo group, receives Placebo.

Sites in Toronto, Calgary and 5 more cities

Phase 2
5 groups
Sites in Calgary, New Westminster and 5 more cities
Recruiting

Official title: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Liver Diseases, Alcoholic · GlaxoSmithKline

Testing Buprenorphine/naloxone for opioid-use disorder

Explore this study →

There are 2 groups in this study. Groups A and B, the comparison group, receive Buprenorphine/naloxone.

Sites in Vancouver, Edmonton and 1 more city

Phase 2
2 groups
Sites in Calgary, Edmonton and 1 more city
Recruiting

Official title: Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Opioid-use Disorder · University of British Columbia

Testing Oral solution against a placebo for alcohol use disorder

Explore this study →

There are 2 groups in this study. Group A receives Oral solution. Group B, the placebo group, receives Oral solution.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Alcohol Use Disorder · Centre for Addiction and Mental Health

Testing Alcohol (Ethanol) against a placebo for alcohol consumption

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives Placebo Beverage. Group B, the comparison group, receives Alcohol (Ethanol).

One site, in Thunder Bay

2 groups
One site, in Thunder Bay
Recruiting

Official title: Ethanol Consumption in the Heat

Alcohol Consumption · Lakehead University

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Substance Use Disorder trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.